Max Chan joins JHL
Biotech as Chief Financial Officer.
Support for the army's JHL
has come from the US Navy and Marine Corps, who believe that a vtol transport would validate their own breakthrough sea basing concept for future sea-to-land operations.
In March 2001, the Tokyo District Court invalidated the imposition of back taxes after determining the loans were all irrecoverable, but the high court overturned it, saying the taxation was appropriate as JHL
had resources that made the loans recoverable.
Primary drivers of the pressure are expected to be continued high levels of credit-related losses at JHF's main operating company, JHL
, and the potential need to provide support for JHL
's statutory surplus in 2003.
Biotech's public offering is made by certain shareholders selling a portion of their current holdings of JHL
Biotech's common stock.
During the economic downturn, our internal risk management controls were elevated to a point that created unintended roadblocks in getting our subcontractor partners paid as quickly as possible," said Ben Stellor, President, JHL
Brazil has become an increasingly attractive target for biosimilar developers such as JHL
because the government strongly supports its domestic manufacturers in working with international partners.
In its first joint effort, JHL
Biotech and Selexis were able to rapidly develop and successfully transfer a biosimilar antibody product.
With this round of financing, JHL
has now secured capital necessary to complete the full development and BLA filing of at least two of its proprietary biosimilar compounds.
Our investors recognize the hard work and progress we have made towards our mission of bringing affordable, quality medicines to Asia through our cross-strait presence in Taiwan and China," said Racho Jordanov, President and CEO of JHL
8, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, and JHL
Biotech, a biopharmaceutical company that develops, manufactures, and commercializes biologic medicines, announced today that they have entered into an agreement to collaborate in the development and commercialization of BL-9020, a novel monoclonal antibody for the treatment of Type 1 diabetes.
The purpose of these contracts, according to the Army, is to define the "art of the possible," the "science of the probable" and the "design of the affordable" for a JHL
VTOL rotorcraft that enables future joint concepts of operations.